Immunobiology Of Natural Killer Cells : Volume 2 book cover
SAVE
$60.00
1st Edition

Immunobiology Of Natural Killer Cells
Volume 2




ISBN 9780367255541
Published September 11, 2019 by CRC Press
240 Pages

 
SAVE ~ $60.00
was $200.00
USD $140.00

Prices & shipping based on shipping country


Preview

Book Description

First published in 1986: This book contributes to the advancing knowledge of reads in the field of NK cells, and will be helpful as a teaching device.

Table of Contents

1. In Vivo Activities of NK Cells Against Primary and Metastatic Tumors in Experimental Animals

Nabil Hanna

2. The Involvement of Natural Killer Cells in Human Malignant Disease

Hugh Pross

3. Impaired NK Cell Profile in Leukemia Patients

Eva Lotzova, Cherylyn A. Savary, and Ronald B. Herberman

4. In Vivo Modulation of NK Activity in Cancer Patients

Peter M. Moy and Sidney H. Golub

5. The Implications of Aberrant Natural Killer (NK) Cell Activity in Nonmalignant Chronic Diseases

Jean E. Merrill

6. NK Cell Role in Regulation of the Growth and Functions of Hemopoietic and Lymphoid Cells

Eva Lotzova

7. Natural Killer Cells Active Against Viral, Bacterial, Protozoan, and Fungal Infections

Patricia A. Fitzgerald and Carlos Lopez

8. Cytokine Secretion and Noncytotoxic Functions of Human Large Granular Lymphocytes

Guiseppe Scala et al.

9. Augmentation of Natural Killer Activity

John R. Ortaldo and Ronald B. Herberman

10. Regulation of NK Cell Activity by Suppressor Cells

Eva Lotzova and Cherylyn A. Savary

11. NK Cell Cloning Technology and Characteristics of NK Cell Clones

Colin G. Brooks

12. A Comparison of Antibody-Dependent Cellular Cytotoxicity (ADCC) and NK Activity

Andrew V. Muchmore

...
View More

Editor(s)

Biography

Dr. Eva Lotzova is Professor of Immunology, Chief of the Division of Immunologenetics at the University of Texas System Cancer, M.D. Anderson Hospital and Tumor Institute, Houston.

Dr. Ronald B. Herberman, formerly Chief of Biological Therapeutics Branch and Acting Associate Director for the Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute, Frederick, Maryland.